# T-CURX

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/t-curx

- Industry: Biotechnology
- Headquarters: Wurzburg, Germany
- Website: www.t-curx.com
- Total disclosed funding: $20M
- Latest round: Series A (Nov 5, 2025)
- Investors on record: 6

## About

T-CURX GmbH, headquartered in Wurzburg, Germany, specializes in innovative personalized immunotherapies leveraging advanced CAR-T cell technology to combat various cancers. Founded in 2017, T-CURX GmbH operates in the field of personalized immunotherapies for cancer treatment. The company has successfully completed one funding deal, raising EUR 17.7 million in a Series A round on December 17, 2025. The round was led by BioMed Partners, with participation from Bayern Kapital, WuXi Biologics (Cayman) Inc., HighLight Capital, and i&i Bio. There is no information on previous pivots or subsidiaries. Details on the founder's history are not available. T-CURX specializes in the development of personalized immunotherapies utilizing CAR-T cell technology. Their product offerings focus on engineered CAR-T cells designed to provide targeted, chemotherapy-free treatments for hematological cancers and solid tumors. The company utilizes advanced engineering techniques, including virus-free transposon-based genetic modification and a modular CAR format, to create tailored therapeutic solutions that enhance flexibility, efficacy, and safety. T-CURX serves healthcare providers and research institutions across Europe and North America, particularly targeting patients facing challenges with conventional CAR-T therapies due to high costs and operational complexities. T-CURX generates revenue primarily through partnerships with healthcare providers, research institutions, and pharmaceutical companies involved in cancer treatment. The company licenses its proprietary CAR-T technologies and engages in joint ventures for product development and commercialization. Revenue streams include milestone payments, royalties, and profit-sharing agreements linked to the success of their CAR-T therapies in clinical settings. While specific pricing plans remain proprietary, T-CURX's focus on cost-effective CAR-T solutions positions the company favorably within the oncology market, aiming to broaden access to essential treatments.With the recent funding of EUR 17.7 million raised in December 2025, T-CURX GmbH plans to accelerate the pre-clinical and clinical development of its non-viral CAR-T pipeline and advance scalable manufacturing technologies. The company is expected to expand its operations into new markets, targeting regions across Europe and North America to enhance accessibility to its innovative therapies. The new funding will be instrumental in supporting these growth initiatives and optimizing their product offerings.

## Funding rounds

- Series A, Nov 5, 2025, $20M — BioMed Partners, Bayern Kapital, HighLight Capital, WuXi Biologics (Cayman) Inc., i&i Bio, ST 4US GmbH

## Investors

- BioMed Partners (https://capitalatlas.ai/funds/biomed-partners) — Series A
- Bayern Kapital (https://capitalatlas.ai/funds/bayern-kapital) — Series A
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series A
- WuXi Biologics (Cayman) Inc. — Series A
- i&i Bio (https://capitalatlas.ai/funds/i-i-bio) — Series A
- ST 4US GmbH — Series A